Previous Close | 1.4500 |
Open | 1.4700 |
Bid | 1.4700 x 1000 |
Ask | 1.5300 x 1300 |
Day's Range | 1.4200 - 1.5300 |
52 Week Range | 1.4100 - 23.7500 |
Volume | |
Avg. Volume | 394,355 |
Market Cap | 6.106M |
Beta (5Y Monthly) | 1.14 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -6.3120 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 12, 2016 |
1y Target Est | 23.75 |
Subscribe to Yahoo Finance Plus to view Fair Value for PTE
PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, announced today that it has entered into securities purchase agreements with a single healthcare-focused institutional investor for the purchase and sale of 1,584,159 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $2.525 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Pol
PolarityTE, Inc. (Nasdaq: PTE) today announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.
PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that the Company will effectuate a 1-for-25 reverse stock split of the Company's issued and outstanding common stock, which will be effective under Delaware law at 4:15 p.m. Eastern Time on Monday, May 16, 2022. As of that time, each 25 shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. A new CUSIP number has